J&J: to present rheumatology results
(CercleFinance.com) - Johnson & Johnson announces that 43 presentations, highlighting its rheumatology portfolio and pipeline, will be presented at the American College of Rheumatology (ACR) 2024 Annual Meeting.
These presentations include oral and plenary sessions with new data on the efficacy of nipocalimab in reducing symptoms in Sjögren's syndrome, as well as the impact of Tremfya in psoriatic arthritis.
Dr. Terence Rooney, Vice President of Rheumatology at J&J, emphasizes that this research demonstrates the company's commitment to innovation in order to improve treatments for rheumatic diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
These presentations include oral and plenary sessions with new data on the efficacy of nipocalimab in reducing symptoms in Sjögren's syndrome, as well as the impact of Tremfya in psoriatic arthritis.
Dr. Terence Rooney, Vice President of Rheumatology at J&J, emphasizes that this research demonstrates the company's commitment to innovation in order to improve treatments for rheumatic diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.